{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=SC&page=27",
    "query": {
      "intervention": "SC",
      "page": 27
    },
    "page_size": 10
  },
  "pagination": {
    "page": 27,
    "page_size": 10,
    "total_count": 3861,
    "total_pages": 387,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=SC&page=28&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=SC&page=26&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-28T23:39:30.267Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01194258",
      "title": "Safety/Efficacy Study of Subcutaneously Injected Prandial Insulins Compared to Insulin Lispro Alone in Patients With Type 2 Diabetes Mellitus",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Diabetes Mellitus, Type II"
      ],
      "interventions": [
        {
          "name": "Insulin lispro",
          "type": "DRUG"
        },
        {
          "name": "Insulin aspart",
          "type": "DRUG"
        },
        {
          "name": "Recombinant human hyaluronidase PH20",
          "type": "DRUG"
        },
        {
          "name": "Insulin glulisine",
          "type": "DRUG"
        },
        {
          "name": "Insulin glargine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Halozyme Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 132,
      "start_date": "2010-08",
      "completion_date": "2011-08",
      "has_results": true,
      "last_update_posted_date": "2014-08-20",
      "last_synced_at": "2026-10-28T23:39:30.267Z",
      "location_count": 22,
      "location_summary": "Concord, California • Encino, California • Escondido, California + 18 more",
      "locations": [
        {
          "city": "Concord",
          "state": "California"
        },
        {
          "city": "Encino",
          "state": "California"
        },
        {
          "city": "Escondido",
          "state": "California"
        },
        {
          "city": "Greenbrae",
          "state": "California"
        },
        {
          "city": "San Mateo",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01194258"
    },
    {
      "nct_id": "NCT05817435",
      "title": "A Phase 1 Bioequivalence Study of Efgartigimod PH20 SC Administered Via a Prefilled Syringe Versus a Vial+Syringe Presentation in Healthy Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Bioequivalence"
      ],
      "interventions": [
        {
          "name": "efgartigimod PH20 SC as a prefilled syringe presentation",
          "type": "BIOLOGICAL"
        },
        {
          "name": "efgartigimod PH20 SC as a vial + syringe presentation",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "argenx",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 120,
      "start_date": "2023-03-13",
      "completion_date": "2023-05-12",
      "has_results": false,
      "last_update_posted_date": "2023-10-31",
      "last_synced_at": "2026-10-28T23:39:30.267Z",
      "location_count": 2,
      "location_summary": "Tempe, Arizona • Lincoln, Nebraska",
      "locations": [
        {
          "city": "Tempe",
          "state": "Arizona"
        },
        {
          "city": "Lincoln",
          "state": "Nebraska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05817435"
    },
    {
      "nct_id": "NCT07808060",
      "title": "A Study of Eloralintide (LY3841136) in Female Participants With Obesity or Overweight",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Obesity",
        "Overweight"
      ],
      "interventions": [
        {
          "name": "Eloralintide",
          "type": "DRUG"
        },
        {
          "name": "Combined oral contraceptive",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 60 Years · Female only"
      },
      "enrollment_count": 34,
      "start_date": "2026-09-15",
      "completion_date": "2027-06",
      "has_results": false,
      "last_update_posted_date": "2026-10-08",
      "last_synced_at": "2026-10-28T23:39:30.267Z",
      "location_count": 2,
      "location_summary": "Daytona Beach, Florida • Dallas, Texas",
      "locations": [
        {
          "city": "Daytona Beach",
          "state": "Florida"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07808060"
    },
    {
      "nct_id": "NCT04627025",
      "title": "Trial to Evaluate Efficacy and Safety of Apraglutide in SBS-IF",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Short Bowel Syndrome"
      ],
      "interventions": [
        {
          "name": "apraglutide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "VectivBio AG",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 164,
      "start_date": "2021-01-26",
      "completion_date": "2024-02-22",
      "has_results": false,
      "last_update_posted_date": "2024-11-27",
      "last_synced_at": "2026-10-28T23:39:30.267Z",
      "location_count": 13,
      "location_summary": "Los Angeles, California • Naples, Florida • Chicago, Illinois + 10 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Naples",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Novi",
          "state": "Michigan"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04627025"
    },
    {
      "nct_id": "NCT07310420",
      "title": "A Trial to Evaluate Ovarian Suppression Following Subcutaneous ZOLADEX 10.8 mg in Premenopausal Women With Early-stage and Advanced HR+ Breast Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Breast Cancer",
        "Early Breast Cancer"
      ],
      "interventions": [
        {
          "name": "ZOLADEX",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "TerSera Therapeutics LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 55 Years · Female only"
      },
      "enrollment_count": 176,
      "start_date": "2026-10-30",
      "completion_date": "2027-07-31",
      "has_results": false,
      "last_update_posted_date": "2026-10-13",
      "last_synced_at": "2026-10-28T23:39:30.267Z",
      "location_count": 26,
      "location_summary": "Hot Springs, Arkansas • Washington D.C., District of Columbia • Ocoee, Florida + 23 more",
      "locations": [
        {
          "city": "Hot Springs",
          "state": "Arkansas"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Ocoee",
          "state": "Florida"
        },
        {
          "city": "Athens",
          "state": "Georgia"
        },
        {
          "city": "Savannah",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07310420"
    },
    {
      "nct_id": "NCT03793608",
      "title": "Study to Evaluate Dupilumab Monotherapy in Pediatric Patients With Peanut Allergy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Peanut Allergy"
      ],
      "interventions": [
        {
          "name": "Dupilumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Regeneron Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "6 Years to 17 Years"
      },
      "enrollment_count": 25,
      "start_date": "2019-03-12",
      "completion_date": "2021-05-12",
      "has_results": true,
      "last_update_posted_date": "2022-05-19",
      "last_synced_at": "2026-10-28T23:39:30.267Z",
      "location_count": 6,
      "location_summary": "Mountain View, California • Tampa, Florida • Indianapolis, Indiana + 3 more",
      "locations": [
        {
          "city": "Mountain View",
          "state": "California"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Ypsilanti",
          "state": "Michigan"
        },
        {
          "city": "Great Neck",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03793608"
    },
    {
      "nct_id": "NCT03315910",
      "title": "Implementing Tobacco Treatment in Low Dose CT Lung Cancer Screening Sites",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Smoking Cessation"
      ],
      "interventions": [
        {
          "name": "Motivational Interviewing (MI)",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Nicotine Replacement Therapy (NRT)",
          "type": "DRUG"
        },
        {
          "name": "Nicotine Lozenge",
          "type": "DRUG"
        },
        {
          "name": "Message Framing",
          "type": "BEHAVIORAL"
        },
        {
          "name": "saliva sample",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL",
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "50 Years to 80 Years"
      },
      "enrollment_count": 807,
      "start_date": "2017-10-10",
      "completion_date": "2026-10",
      "has_results": false,
      "last_update_posted_date": "2025-11-24",
      "last_synced_at": "2026-10-28T23:39:30.267Z",
      "location_count": 18,
      "location_summary": "Los Angeles, California • Walnut Creek, California • La Grange, Georgia + 14 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Walnut Creek",
          "state": "California"
        },
        {
          "city": "La Grange",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Kankakee",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03315910"
    },
    {
      "nct_id": "NCT02027298",
      "title": "Abatacept for Patients With Inflammatory Arthritis Associated With Sjögren's Syndrome: an Open-Label Phase II Study",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Primary Sjogren's Syndrome",
        "Secondary Sjogren's Syndrome",
        "Inflammatory Arthritis",
        "Rheumatoid Arthritis"
      ],
      "interventions": [
        {
          "name": "Abatacept",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "The Cleveland Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2013-11",
      "completion_date": "2014-10",
      "has_results": false,
      "last_update_posted_date": "2017-01-09",
      "last_synced_at": "2026-10-28T23:39:30.267Z",
      "location_count": 1,
      "location_summary": "Cleveland, Ohio",
      "locations": [
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02027298"
    },
    {
      "nct_id": "NCT04365387",
      "title": "A Study to Assess Immunization Responses in Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis Treated With Nemolizumab",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Dermatitis, Atopic"
      ],
      "interventions": [
        {
          "name": "Nemolizumab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Galderma R&D",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "54 Years",
        "sex": "ALL",
        "summary": "12 Years to 54 Years"
      },
      "enrollment_count": 242,
      "start_date": "2020-03-05",
      "completion_date": "2023-07-07",
      "has_results": true,
      "last_update_posted_date": "2026-06-01",
      "last_synced_at": "2026-10-28T23:39:30.267Z",
      "location_count": 64,
      "location_summary": "Phoenix, Arizona • Scottsdale, Arizona • Fort Smith, Arkansas + 53 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Fort Smith",
          "state": "Arkansas"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Canoga Park",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04365387"
    },
    {
      "nct_id": "NCT00584038",
      "title": "Improving Adolescent Adherence to Hormonal Contraception",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Contraception"
      ],
      "interventions": [
        {
          "name": "educational instruction and phone follow-up",
          "type": "BEHAVIORAL"
        },
        {
          "name": "educational instruction in clinic",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "The University of Texas Medical Branch, Galveston",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": "24 Years",
        "sex": "FEMALE",
        "summary": "16 Years to 24 Years · Female only"
      },
      "enrollment_count": 1155,
      "start_date": "2006-01",
      "completion_date": "2012-03",
      "has_results": false,
      "last_update_posted_date": "2013-05-24",
      "last_synced_at": "2026-10-28T23:39:30.267Z",
      "location_count": 1,
      "location_summary": "Galveston, Texas",
      "locations": [
        {
          "city": "Galveston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00584038"
    }
  ]
}